Immunovant (IMVT) Equity Average (2019 - 2026)

Immunovant has reported Equity Average for 8 years, with the latest figure at $919.4 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 73.45% year-over-year to $919.4 million; the trailing twelve-month figure through Mar 2026 stood at $919.4 million (up 73.45% YoY), and the FY2026 full-year result was $780.0 million, up 17.72% from the prior year.
• Equity Average for Q1 2026 stood at $919.4 million, up from $752.9 million in the prior quarter.
• The five-year high for Equity Average was $919.4 million in Q1 2026, with the low at $275.8 million in Q3 2023.
• Historically, Equity Average has averaged $516.2 million across 5 years, with a median of $487.5 million in 2022.
• Annual changes were most pronounced in 2023 — Equity Average tumbled 33.71% — and 2025, when it surged 87.84%.
• Immunovant's Equity Average stood at $405.2 million in 2022, then grew by 14.9% to $465.6 million in 2023, then dropped by 13.91% to $400.8 million in 2024, then surged by 87.84% to $752.9 million in 2025, then gained by 22.11% to $919.4 million in 2026.
• The last three Equity Average figures came in at $919.4 million (Q1 2026), $752.9 million (Q4 2025), and $564.1 million (Q3 2025), per Business Quant data.